Comments
Pharmaceutical company Hetero Healthcare is set to deliver the first set of 20,000 vials of its Covid-19 drug, Covifor.
Hyderabad-based Hetero has already obtained approval from the Drug Control General of India (DCGI) for the anti-viral drug.
Covifor is the first generic brand of remdesivir that is indicated for the treatment of adults and children hospitalised with severe symptoms of Covid-19.
The delivery would be done in two equal lots of 10,000 each. One lot will be immediately supplied across Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra.
The other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Kochi, Thiruvananthapuram and Goa within a week, in order to meet the emergency requirements.
“We are working closely with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country,” said M. Srinivas Reddy, Managing Director, Hetero Healthcare, in a press release.
The drug is available in 100 mg vials (injectable). It needs to be administered intravenously in a hospital critical-care setting under the supervision of a registered medical practitioner.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.